Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.

IF 37.3 1区 医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Mmwr Surveillance Summaries Pub Date : 2015-10-16 DOI:10.15585/mmwr.ss6409a1
Leonard J Paulozzi, Gail K Strickler, Peter W Kreiner, Caitlin M Koris
{"title":"Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.","authors":"Leonard J Paulozzi,&nbsp;Gail K Strickler,&nbsp;Peter W Kreiner,&nbsp;Caitlin M Koris","doi":"10.15585/mmwr.ss6409a1","DOIUrl":null,"url":null,"abstract":"<p><strong>Problem/condition: </strong>Drug overdose is the leading cause of injury death in the United States. The death rate from drug overdose in the United States more than doubled during 1999-2013, from 6.0 per 100,000 population in 1999 to 13.8 in 2013. The increase in drug overdoses is attributable primarily to the misuse and abuse of prescription drugs, especially opioid analgesics, sedatives/tranquilizers, and stimulants. Such drugs are prescribed widely in the United States, with substantial variation by state. Certain patients obtain drugs for nonmedical use or resale by obtaining overlapping prescriptions from multiple prescribers. The risk for overdose is directly associated with the use of multiple prescribers and daily dosages of >100 morphine milligram equivalents (MMEs) per day.</p><p><strong>Period covered: </strong>2013.</p><p><strong>Description of system: </strong>The Prescription Behavior Surveillance System (PBSS) is a public health surveillance system that allows public health authorities to characterize and quantify the use and misuse of prescribed controlled substances. PBSS began collecting data in 2012 and is funded by CDC and the Food and Drug Administration. PBSS uses standard metrics to measure prescribing rates per 1,000 state residents by demographic variables, drug type, daily dose, and source of payment. Data from the system can be used to calculate rates of misuse by certain behavioral measures such as use of multiple prescribers and pharmacies within specified time periods. This report is based on 2013 de-identified data (most recent available) that represent approximately one fourth of the U.S.</p><p><strong>Population: </strong>Data were submitted quarterly by prescription drug monitoring programs (PDMPs) in eight states (California, Delaware, Florida, Idaho, Louisiana, Maine, Ohio, and West Virginia) that routinely collect data on every prescription for a controlled substance to help law enforcement and health care providers identify misuse or abuse of such drugs.</p><p><strong>Results: </strong>In all eight states, opioid analgesics were prescribed approximately twice as often as stimulants or benzodiazepines. Prescribing rates by drug class varied widely by state: twofold for opioids, fourfold for stimulants, almost twofold for benzodiazepines, and eightfold for carisoprodol, a muscle relaxant. Rates for opioids and benzodiazepines were substantially higher for females than for males in all states. In most states, opioid prescribing rates peaked in either the 45-54 years or the 55-64 years age group. Benzodiazepine prescribing rates increased with age. Louisiana ranked first in opioid prescribing, and Delaware and Maine had relatively high rates of use of long-acting (LA) or extended-release (ER) opioids. Delaware and Maine ranked highest in both mean daily opioid dosage and in the percentage of opioid prescriptions written for >100 MMEs per day. The top 1% of prescribers wrote one in four opioid prescriptions in Delaware, compared with one in eight in Maine. For the five states whose PDMPs collected the method of payment, the percentage of controlled substance prescriptions paid for in cash varied almost threefold, and the percentage paid by Medicaid varied sixfold. In West Virginia, for 1 of every 5 days of treatment with an opioid, the patient also was taking a benzodiazepine. Multiple-provider episode rates were highest in Ohio and lowest in Louisiana.</p><p><strong>Interpretation: </strong>This report presents rates of population-based prescribing and behavioral measures of drug misuse in the general population that have not been available previously for comparison among demographic groups and states. The higher prescribing rates for opioids among women compared with men are consistent with a higher self-reported prevalence of certain common types of pain, such as lower back pain among women. The trend in opioid prescribing rates with age is consistent with an increase in the prevalence of chronic pain with age, but the increasing prescribing rates of benzodiazepines with age is not consistent with the fact that anxiety is most common among persons aged 30-44 years. The variation among states in the type of opioid or benzodiazepine of choice is unexplained. Most opioid prescribing occurs among a small minority of prescribers. Most of the prescriptions by top-decile prescribers probably are written by general, family medicine, internal medicine, and midlevel practitioners. The source of payment varied by state, for reasons that are unclear. Persons who are prescribed opioids also are commonly prescribed benzodiazepine sedatives despite the risk for additive depressant effects.</p><p><strong>Public health actions: </strong>States can use their prescription drug monitoring programs to generate population-based measures for the prescribing of controlled substances and for behaviors that suggest their misuse. Comparing data with other states and tracking changes in these measures over time can be useful in measuring the effect of policies designed to reduce prescription drug misuse.</p>","PeriodicalId":48549,"journal":{"name":"Mmwr Surveillance Summaries","volume":"64 9","pages":"1-14"},"PeriodicalIF":37.3000,"publicationDate":"2015-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"141","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mmwr Surveillance Summaries","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15585/mmwr.ss6409a1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 141

Abstract

Problem/condition: Drug overdose is the leading cause of injury death in the United States. The death rate from drug overdose in the United States more than doubled during 1999-2013, from 6.0 per 100,000 population in 1999 to 13.8 in 2013. The increase in drug overdoses is attributable primarily to the misuse and abuse of prescription drugs, especially opioid analgesics, sedatives/tranquilizers, and stimulants. Such drugs are prescribed widely in the United States, with substantial variation by state. Certain patients obtain drugs for nonmedical use or resale by obtaining overlapping prescriptions from multiple prescribers. The risk for overdose is directly associated with the use of multiple prescribers and daily dosages of >100 morphine milligram equivalents (MMEs) per day.

Period covered: 2013.

Description of system: The Prescription Behavior Surveillance System (PBSS) is a public health surveillance system that allows public health authorities to characterize and quantify the use and misuse of prescribed controlled substances. PBSS began collecting data in 2012 and is funded by CDC and the Food and Drug Administration. PBSS uses standard metrics to measure prescribing rates per 1,000 state residents by demographic variables, drug type, daily dose, and source of payment. Data from the system can be used to calculate rates of misuse by certain behavioral measures such as use of multiple prescribers and pharmacies within specified time periods. This report is based on 2013 de-identified data (most recent available) that represent approximately one fourth of the U.S.

Population: Data were submitted quarterly by prescription drug monitoring programs (PDMPs) in eight states (California, Delaware, Florida, Idaho, Louisiana, Maine, Ohio, and West Virginia) that routinely collect data on every prescription for a controlled substance to help law enforcement and health care providers identify misuse or abuse of such drugs.

Results: In all eight states, opioid analgesics were prescribed approximately twice as often as stimulants or benzodiazepines. Prescribing rates by drug class varied widely by state: twofold for opioids, fourfold for stimulants, almost twofold for benzodiazepines, and eightfold for carisoprodol, a muscle relaxant. Rates for opioids and benzodiazepines were substantially higher for females than for males in all states. In most states, opioid prescribing rates peaked in either the 45-54 years or the 55-64 years age group. Benzodiazepine prescribing rates increased with age. Louisiana ranked first in opioid prescribing, and Delaware and Maine had relatively high rates of use of long-acting (LA) or extended-release (ER) opioids. Delaware and Maine ranked highest in both mean daily opioid dosage and in the percentage of opioid prescriptions written for >100 MMEs per day. The top 1% of prescribers wrote one in four opioid prescriptions in Delaware, compared with one in eight in Maine. For the five states whose PDMPs collected the method of payment, the percentage of controlled substance prescriptions paid for in cash varied almost threefold, and the percentage paid by Medicaid varied sixfold. In West Virginia, for 1 of every 5 days of treatment with an opioid, the patient also was taking a benzodiazepine. Multiple-provider episode rates were highest in Ohio and lowest in Louisiana.

Interpretation: This report presents rates of population-based prescribing and behavioral measures of drug misuse in the general population that have not been available previously for comparison among demographic groups and states. The higher prescribing rates for opioids among women compared with men are consistent with a higher self-reported prevalence of certain common types of pain, such as lower back pain among women. The trend in opioid prescribing rates with age is consistent with an increase in the prevalence of chronic pain with age, but the increasing prescribing rates of benzodiazepines with age is not consistent with the fact that anxiety is most common among persons aged 30-44 years. The variation among states in the type of opioid or benzodiazepine of choice is unexplained. Most opioid prescribing occurs among a small minority of prescribers. Most of the prescriptions by top-decile prescribers probably are written by general, family medicine, internal medicine, and midlevel practitioners. The source of payment varied by state, for reasons that are unclear. Persons who are prescribed opioids also are commonly prescribed benzodiazepine sedatives despite the risk for additive depressant effects.

Public health actions: States can use their prescription drug monitoring programs to generate population-based measures for the prescribing of controlled substances and for behaviors that suggest their misuse. Comparing data with other states and tracking changes in these measures over time can be useful in measuring the effect of policies designed to reduce prescription drug misuse.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
管制物质处方模式——处方行为监测系统,八个州,2013。
问题/状况:在美国,药物过量是造成伤害和死亡的主要原因。1999年至2013年期间,美国药物过量死亡率增加了一倍多,从1999年的每10万人6.0人增加到2013年的13.8人。药物过量的增加主要是由于处方药的误用和滥用,特别是阿片类镇痛药、镇静剂/镇静剂和兴奋剂。这类药物在美国被广泛开处方,各州有很大差异。某些患者通过从多个处方者处获得重叠的处方获得非医疗用途或转售的药物。过量风险与使用多个处方者和每日剂量>100吗啡毫克当量(MMEs)直接相关。涵盖时间:2013年。系统描述:处方行为监测系统(PBSS)是一个公共卫生监测系统,使公共卫生当局能够描述和量化处方受控物质的使用和滥用。PBSS于2012年开始收集数据,由疾病预防控制中心和食品药物管理局资助。PBSS使用标准指标,根据人口统计变量、药物类型、日剂量和支付来源来衡量每1000名州居民的处方率。来自该系统的数据可用于计算某些行为测量的误用率,例如在指定时间段内使用多个处方者和药房。本报告基于2013年的去识别数据(最新的可用数据),这些数据约占美国人口的四分之一:数据由八个州(加利福尼亚州、特拉华州、佛罗里达州、爱达荷州、路易斯安那州、缅因州、俄亥俄州和西弗吉尼亚州)的处方药监测项目(PDMPs)每季度提交一次,这些项目定期收集受控物质的每个处方数据,以帮助执法部门和医疗保健提供者识别误用或滥用此类药物。结果:在所有八个州,阿片类镇痛药的处方频率大约是兴奋剂或苯二氮卓类药物的两倍。药物类别的处方率因州而异:阿片类药物是两倍,兴奋剂是四倍,苯二氮卓类药物几乎是两倍,肌肉松弛剂卡异丙醇是八倍。在所有州,女性使用阿片类药物和苯二氮卓类药物的比例都大大高于男性。在大多数州,阿片类药物处方率在45-54岁或55-64岁年龄组达到峰值。苯二氮卓类药物的处方率随着年龄的增长而增加。路易斯安那州在阿片类药物处方方面排名第一,特拉华州和缅因州使用长效(LA)或缓释(ER)阿片类药物的比例相对较高。特拉华州和缅因州在平均每日阿片类药物剂量和每天超过100 MMEs的阿片类药物处方百分比方面均排名最高。在特拉华州,前1%的处方者开出了四分之一的阿片类药物处方,而在缅因州,这一比例为八分之一。在pdmp收集支付方式的五个州,用现金支付的管制药物处方的百分比变化了近三倍,用医疗补助支付的百分比变化了六倍。在西弗吉尼亚州,在每5天接受阿片类药物治疗的1天中,患者同时服用苯二氮卓类药物。多家医院的发生率在俄亥俄州最高,在路易斯安那州最低。解释:本报告提出了以人群为基础的处方率和普通人群药物滥用的行为测量,这是以前无法在人口群体和州之间进行比较的。与男性相比,女性的阿片类药物处方率较高,这与某些常见类型的疼痛(如女性腰痛)自我报告的患病率较高一致。阿片类药物处方率随年龄增长的趋势与慢性疼痛患病率随年龄增长的趋势一致,但苯二氮卓类药物处方率随年龄增长的趋势与焦虑在30-44岁人群中最常见的事实不一致。各州在阿片类药物或苯二氮卓类药物选择类型上的差异是无法解释的。大多数阿片类药物处方发生在少数处方者中。前十分位开处方者开出的大多数处方可能是由全科、家庭医学、内科和中级医生开出的。支付的来源因州而异,原因尚不清楚。服用阿片类药物的人通常也服用苯二氮卓类镇静剂,尽管存在附加抑制剂作用的风险。公共卫生行动:各国可利用其处方药监测方案,针对管制药物的处方和表明滥用这些药物的行为制定以人口为基础的措施。将数据与其他州进行比较,并跟踪这些措施随时间的变化,对于衡量旨在减少处方药滥用的政策的效果是有用的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Mmwr Surveillance Summaries
Mmwr Surveillance Summaries PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
60.50
自引率
1.20%
发文量
9
期刊介绍: The Morbidity and Mortality Weekly Report (MMWR) Series, produced by the Centers for Disease Control and Prevention (CDC), is commonly referred to as "the voice of CDC." Serving as the primary outlet for timely, reliable, authoritative, accurate, objective, and practical public health information and recommendations, the MMWR is a crucial publication. Its readership primarily includes physicians, nurses, public health practitioners, epidemiologists, scientists, researchers, educators, and laboratorians.
期刊最新文献
Laboratory-Confirmed Influenza-Associated Hospitalizations Among Children and Adults - Influenza Hospitalization Surveillance Network, United States, 2010-2023. Surveillance for Violent Deaths - National Violent Death Reporting System, 48 States, the District of Columbia, and Puerto Rico, 2021. Progress Toward Tuberculosis Elimination and Tuberculosis Program Performance - National Tuberculosis Indicators Project, 2016-2022. Sentinel Enhanced Dengue Surveillance System - Puerto Rico, 2012-2022. Preventable Premature Deaths from the Five Leading Causes of Death in Nonmetropolitan and Metropolitan Counties, United States, 2010-2022.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1